Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib
Open Access
- 13 May 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 102 (8), 965-971
- https://doi.org/10.1002/bjs.9818
Abstract
Neoadjuvant imatinib therapy was usefulKeywords
Funding Information
- National Institute for Health Research
This publication has 29 references indexed in Scilit:
- Gastrointestinal stromal tumourThe Lancet, 2013
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal TumorJAMA, 2012
- Epidemiology of gastrointestinal stromal tumours: Single-institution experience and clinical presentation over three decadesCancer Epidemiology, 2011
- Histopathology of gastrointestinal stromal tumorJournal of Surgical Oncology, 2011
- A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European regionBritish Journal of Cancer, 2010
- Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)European Journal of Surgical Oncology, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Gastrointestinal stromal tumors in Iceland, 1990–2003: The Icelandic GIST study, a population‐based incidence and pathologic risk stratification studyInternational Journal of Cancer, 2005
- The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases from 1992 to 2000The American Journal of Gastroenterology, 2005
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998